232 related articles for article (PubMed ID: 18955797)
1. Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.
Jung SC; Park JW; Oh HJ; Choi JO; Seo KI; Park ES; Park HY
J Korean Med Sci; 2008 Oct; 23(5):877-83. PubMed ID: 18955797
[TBL] [Abstract][Full Text] [Related]
2. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
Ding Z; Georgiev P; Thöny B
Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
[TBL] [Abstract][Full Text] [Related]
3. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
4. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
5. Reversal of gene expression profile in the phenylketonuria mouse model after adeno-associated virus vector-mediated gene therapy.
Oh HJ; Lee H; Park JW; Rhee H; Koo SK; Kang S; Jo I; Jung SC
Mol Genet Metab; 2005 Dec; 86 Suppl 1():S124-32. PubMed ID: 16150627
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer.
Fang B; Eisensmith RC; Li XH; Finegold MJ; Shedlovsky A; Dove W; Woo SL
Gene Ther; 1994 Jul; 1(4):247-54. PubMed ID: 7584088
[TBL] [Abstract][Full Text] [Related]
7. Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer.
Nagasaki Y; Matsubara Y; Takano H; Fujii K; Senoo M; Akanuma J; Takahashi K; Kure S; Hara M; Kanegae Y; Saito I; Narisawa K
Pediatr Res; 1999 Apr; 45(4 Pt 1):465-73. PubMed ID: 10203136
[TBL] [Abstract][Full Text] [Related]
8. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector.
Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A
J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099
[TBL] [Abstract][Full Text] [Related]
9. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
10. Recovery of neurogenic amines in phenylketonuria mice after liver-targeted gene therapy.
Yagi H; Sanechika S; Ichinose H; Sumi-Ichinose C; Mizukami H; Urabe M; Ozawa K; Kume A
Neuroreport; 2012 Jan; 23(1):30-4. PubMed ID: 22107842
[TBL] [Abstract][Full Text] [Related]
11. Impact of the phenylalanine hydroxylase gene on maternal phenylketonuria outcome.
Güttler F; Azen C; Guldberg P; Romstad A; Hanley WB; Levy HL; Matalon R; Rouse BM; Trefz F; de la Cruz F; Koch R
Pediatrics; 2003 Dec; 112(6 Pt 2):1530-3. PubMed ID: 14654659
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II.
Sun B; Zhang H; Franco LM; Young SP; Schneider A; Bird A; Amalfitano A; Chen YT; Koeberl DD
Mol Ther; 2005 Jan; 11(1):57-65. PubMed ID: 15585406
[TBL] [Abstract][Full Text] [Related]
13. Characterization of transgenic mice with the expression of phenylalanine hydroxylase and GTP cyclohydrolase I in the skin.
Christensen R; Alhonen L; Wahlfors J; Jakobsen M; Jensen TG
Exp Dermatol; 2005 Jul; 14(7):535-42. PubMed ID: 15946242
[TBL] [Abstract][Full Text] [Related]
14. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B
Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydrobiopterin protects phenylalanine hydroxylase activity in vivo: implications for tetrahydrobiopterin-responsive hyperphenylalaninemia.
Thöny B; Ding Z; Martínez A
FEBS Lett; 2004 Nov; 577(3):507-11. PubMed ID: 15556637
[TBL] [Abstract][Full Text] [Related]
16. Altered brain gene expression profiles associated with the pathogenesis of phenylketonuria in a mouse model.
Park JW; Park ES; Choi EN; Park HY; Jung SC
Clin Chim Acta; 2009 Mar; 401(1-2):90-9. PubMed ID: 19073163
[TBL] [Abstract][Full Text] [Related]
17. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria.
Rebuffat A; Harding CO; Ding Z; Thöny B
Hum Gene Ther; 2010 Apr; 21(4):463-77. PubMed ID: 19916803
[TBL] [Abstract][Full Text] [Related]
18. Validation of PAH genotype-based predictions of metabolic phenylalanine hydroxylase deficiency phenotype: investigation of PKU/MHP patients from Lithuania.
Kasnauskiene J; Cimbalistiene L; Kucinskas V
Med Sci Monit; 2003 Mar; 9(3):CR142-6. PubMed ID: 12640344
[TBL] [Abstract][Full Text] [Related]
19. Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.
Gámez A; Sarkissian CN; Wang L; Kim W; Straub M; Patch MG; Chen L; Striepeke S; Fitzpatrick P; Lemontt JF; O'Neill C; Scriver CR; Stevens RC
Mol Ther; 2005 Jun; 11(6):986-9. PubMed ID: 15922970
[TBL] [Abstract][Full Text] [Related]
20. The PAH gene, phenylketonuria, and a paradigm shift.
Scriver CR
Hum Mutat; 2007 Sep; 28(9):831-45. PubMed ID: 17443661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
